Kymera Therapeutics (KYMR) Receivables (2020 - 2025)

Kymera Therapeutics (KYMR) has 6 years of Receivables data on file, last reported at $40.0 million in Q2 2025.

• On a quarterly basis, Receivables rose 1073.71% year-over-year to $40.0 million in Q2 2025; TTM through Jun 2025 was $40.0 million, a 1073.71% increase from a year earlier, with the FY2024 full-year figure at $1.9 million, down 91.61% from the prior year.
• Receivables for Q2 2025 stood at $40.0 million, roughly flat from $40.0 million in the prior quarter.
• Over the last five years, Receivables for KYMR reached as high as $40.0 million in Q1 2025 and fell as low as $235000.0 in Q4 2021.
• Historically, Receivables has averaged $8.9 million across 5 years, with a median of $3.7 million in 2024.
• Across the five-year window, Receivables tumbled 91.8% in 2024 and soared 1073.71% in 2025, its largest moves.
• Year by year, Receivables stood at $235000.0 in 2021, then soared by 979.57% to $2.5 million in 2022, then jumped by 787.82% to $22.5 million in 2023, then tumbled by 91.8% to $1.8 million in 2024, then jumped by 2065.67% to $40.0 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $40.0 million in Q2 2025, $40.0 million in Q1 2025, and $1.8 million in Q4 2024.